抗体治療薬市場：フォーマット、投与経路、供給源、疾患領域、エンドユーザー別-2024-2030年の世界予測

抗体治療薬市場規模は、2023年に2,487億9,000万米ドルと推定され、2024年には2,857億7,000万米ドルに達し、CAGR 14.89％で2030年には6,575億米ドルに達すると予測されています。

抗体治療薬は、免疫系が病気と闘う能力を模倣または強化するために抗体を使用する一群の治療法です。抗体治療薬の精度の高さは、従来の薬剤よりも高い特異性と低い毒性プロファイルを提供するオーダーメイド治療を可能にし、がん、自己免疫疾患、感染症を含む様々な症状の治療に効果的です。慢性疾患の増加と世界のヘルスケア支出の増加により、抗体治療薬の採用が増加しています。しかし、開発に伴う高額なコストや長く複雑な規制当局の承認が、抗体治療薬の普及を制限しています。とはいえ、医療技術の進歩は、より生産性の高い抗体作製につながっています。加えて、次世代抗体の出現や、がん治療・ケアに対する政府の支援イニシアティブは、抗体治療薬市場に潜在的な機会を提供すると期待されています。

地域別インサイト

南北アメリカでは、確立された研究開発エコシステム、広範な特許ポートフォリオ、高いヘルスケア支出に支えられ、抗体治療薬市場は力強い成長を示しています。さらに、南北アメリカには数多くのバイオ医薬品大手が存在し、モノクローナル抗体や新薬の開発に多大な資源を投入しています。アジア太平洋地域は、ヘルスケア・インフラの成長と慢性疾患の増加により、抗体治療薬に対するニーズが急増しました。さらに、アジア太平洋地域は、強力な研究機関と政府の支援政策に支えられた個別化医療と抗体開発の進歩により、抗体治療薬市場の成長を目の当たりにしています。強力な製薬産業、広範な研究イニシアティブ、包括的な知的財産権の枠組みを持つ欧州連合（EU）諸国は、抗体治療薬の展望において極めて重要です。さらに、中東やアフリカの国々は、最先端の医療施設やヘルスケア・イノベーションに投資しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗体治療薬市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront（F）、Pathfinder（P）、Niche（N）、Vital（V）に分類されます。

市場シェア分析

市場シェア分析は、抗体治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、抗体治療薬市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • さまざまながんや感染症の発生率の上昇
    • 世界中で増加する創薬活動
    • 抗体治療と療法へのアクセスを促進する政府の取り組み
  • 抑制要因
    • 抗体治療薬の製品リコールの発生と厳格な承認ガイドライン
  • 機会
    • 抗体治療薬の臨床開発の進歩
    • 新規抗体療法および治療法の承認が進行中
  • 課題
    • さまざまな治療法に伴う不十分な有効性と副作用
• 市場セグメンテーション分析
  • 形式：規制当局による臨床使用の承認が多数あるため、モノクローナル抗体の活用が進んでいる
  • 投与経路：抗体治療薬の静脈内投与の使用が増加している
  • 出典：生体適合性のためヒト抗体の使用が増加
  • 疾患領域：感染症に関する抗体治療薬の使用が急増
  • エンドユーザー：病院における抗体治療薬の使用法の進化
• 市場動向分析
  • 南北アメリカにおける政府の資金援助と世界的に有名な製薬企業によるパートナーシップ活動に支えられた抗体治療薬の先進的な研究開発活動
  • 慢性疾患と感染症の負担が増大し、アジア太平洋地域で抗体治療薬の必要性が高まっている
  • EMEA地域でのバイオテクノロジー企業の拡大と相まって、臨床試験が進行中
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 抗体治療薬市場フォーマット別

• 抗体フラグメント
• 二重特異性抗体
• モノクローナル抗体
• ポリクローナル抗体

第7章 抗体治療薬市場：投与経路別

• 静脈内
• 皮下

第8章 抗体治療薬市場：ソース別

• キメラ
• 人間
• 人間化

第9章 抗体治療薬市場疾患領域別

• 自己免疫疾患および炎症性疾患
• 血液学
• 免疫学
• 神経学
• 腫瘍学
• 骨学

第10章 抗体治療薬市場：エンドユーザー別

• 病院
• 長期介護施設

第11章 南北アメリカの抗体治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の抗体治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの抗体治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • SystImmuneとブリストル・マイヤーズスクイブ、BL-B01D1の開発と商品化に関する世界戦略的提携契約を発表
  • アッヴィとビッグハット・バイオサイエンス、人工知能と機械学習を活用した次世代治療用抗体の発見に向けた調査協力を発表
  • アッヴィ、主力のがん治療薬ELAHERE（ミルベツキシマブソラビタンシン-ジンクス）を含むイミュノジェンを買収し、固形腫瘍ポートフォリオを拡大
  • MBrace Therapeutics、革新的な抗体薬物複合体候補の腫瘍学パイプラインを前進させるため、シリーズB資金調達で8,500万米ドルを調達
  • サリプロ、イコサゲンと提携しモノクローナル抗体療法を開発
  • AbCelleraとIncyteが腫瘍学における治療用抗体で提携
  • 日本、バイオアークティックのパーキンソン病抗体の特許を取得
  • 米国FDA、多発性骨髄腫の重篤な前治療歴を持つ患者の治療に用いられる初の二重特異性療法TALVEYを承認
  • クロスボウ・セラピューティクス、シリーズA資金調達で8,000万米ドルを調達し、抗体治療薬の発展に着手
  • クロスボウ・セラピューティクス、シリーズA資金調達で8,000万米ドルを調達し、抗体治療薬の発展に着手
  • Pyxis Oncologyが抗体治療薬社Apexigenを買収
  • メルク、108億米ドルの買収でmAbを開発へ
  • ジェンマブとアルジェンエックスが免疫学と腫瘍学における抗体療法の進歩に向けて提携

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 55. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 56. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 63. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 64. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 65. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 66. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 67. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 68. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 73. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 74. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 75. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 76. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 77. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 78. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 81. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 82. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 83. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 84. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 85. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 86. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 87. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 88. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 89. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 90. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 91. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 92. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 95. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 96. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 97. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 98. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 99. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 100. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 101. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 102. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 107. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 108. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 109. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 110. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 111. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 112. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 113. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 114. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 118. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 120. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 122. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 124. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 126. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 127. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 128. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 129. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 130. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 131. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 132. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 133. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 134. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 135. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 136. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 137. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 138. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 139. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 140. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 141. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 142. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 143. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 144. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 145. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 146. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 147. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 148. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 149. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 150. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 151. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 152. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 153. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 154. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 155. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 156. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 157. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 158. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 159. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 160. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 161. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 162. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 163. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 164. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 165. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 166. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 167. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 168. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 169. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 170. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 171. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 172. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 173. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 174. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 175. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 176. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 177. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 178. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 179. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 180. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 181. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 182. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 183. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 184. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 185. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 186. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 187. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 188. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 189. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 190. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 191. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 192. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 193. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 194. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 195. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 196. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 197. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 198. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 199. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 200. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 201. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 202. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 203. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 204. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 205. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 206. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 208. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 210. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 212. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 214. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 216. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 217. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 218. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 219. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 220. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 221. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 222. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 223. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 224. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 225. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 226. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 227. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 228. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 229. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 230. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 231. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 232. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 233. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 234. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 235. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 236. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 237. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 238. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 239. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 240. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 241. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 242. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 243. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 244. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 245. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 246. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 259. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 260. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 261. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 262. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 263. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 264. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 265. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 266. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 267. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 268. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 269. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 270. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 271. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 272. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 273. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 274. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 275. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 276. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 277. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 278. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 279. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 280. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 281. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 282. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 283. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 284. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 285. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 286. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 287. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 288. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 289. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 290. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 291. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 292. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 293. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 294. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 295. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 296. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 297. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 298. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 299. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 300. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 301. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 302. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 303. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 304. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 305. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 306. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 307. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 308. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 309. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 310. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 311. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 312. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 313. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 314. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 315. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 316. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 317. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 318. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 319. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 320. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 321. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 322. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 323. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 324. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 325. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 326. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 327. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 328. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 329. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 330. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 331. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 332. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 333. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 334. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 335. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
• TABLE 336. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
• TABLE 337. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 338. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 339. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
• TABLE 340. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
• TABLE 341. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 342. NIGERIA ANTIBODY TH

[197 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.

Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.

Regional Insights

In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.

Market Insights

• Market Dynamics

The market dynamics represent an ever-changing landscape of the Antibody Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Rising incidences of various cancers and infectious diseases
  • Increasing number of drug discovery activities worldwide
  • Government initiatives to promote access to antibody treatments and therapies

• Market Restraints
  • Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines

• Market Opportunities
  • Advancements in the clinical development of antibody therapeutics
  • Ongoing approvals for novel antibody therapies and treatments

• Market Challenges
  • Insufficient efficacy and adverse effects associated with various treatments
• Market Segmentation Analysis
  • Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
  • Route of Administration: Growing usage of intravenous administration of antibody therapeutics
  • Source: Increasing use of human antibodies due to its biocompatible nature
  • Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
  • End User: Evolving usage of antibody therapeutics in hospitals

• Market Disruption Analysis
• Porter's Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antibody Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

SystImmune entered into a pivotal license and collaboration agreement with Bristol Myers Squibb that focuses on the co-development and commercialization of the innovative BL-B01D1, an EGFRxHER3 bispecific antibody-drug conjugate (ADC) that is promising as a first-in-class therapy. Currently undergoing a Phase 1 clinical trial targeting non-small cell lung cancer (NSCLC), BL-B01D1 has already exhibited significant anti-tumor activity and a well-managed safety profile across various solid tumors. [Published On: 2023-12-11]

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

AbbVie Inc. partnered with BigHat Biosciences to drive the creation of cutting-edge therapeutic antibodies for oncology and neuroscience. This collaboration aims to streamline the discovery and optimization of superior antibodies for several key therapeutic targets. This initiative reflects the company's dedication to integrating AI and ML advancements into the drug development workflow to expedite the delivery of effective treatments. [Published On: 2023-12-05]

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

AbbVie announced the acquisition of ImmunoGen, a significant development that includes control of rights of ELAHERE (mirvetuximab soravtansine-gynx), ImmunoGen's premier cancer therapy. This acquisition is a testament to AbbVie's commitment to expanding its solid tumor treatment capabilities, positioning it to better address the complexities of cancer care. [Published On: 2023-11-30]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antibody Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Format
  • Antibody Fragment
  • Bispecific Antibody
  • Monoclonal Antibody
  • Polyclonal Antibody

• Route of Administration
  • Intravenous
  • Subcutaneous

• Source
  • Chimeric
  • Human
  • Humanized

• Disease Areas
  • Autoimmune & Inflammatory Diseases
  • Hematology
  • Immunology
  • Neurology
  • Oncology
  • Osteology

• End User
  • Hospitals
  • Long-term Care Facilities

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of various cancers and infectious diseases
    • 5.1.1.2. Increasing number of drug discovery activities worldwide
    • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
    • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
  • 5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
  • 5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
  • 5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
  • 5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
• 5.3. Market Trend Analysis
  • 5.3.1. Advanced R&D activities in antibody therapeutics backed by government funding and partnership activities by global established pharmaceutical companies in Americas
  • 5.3.2. Growing burden of chronic and infectious diseases creating need for antibody therapeutics in the Asia-Pacific
  • 5.3.3. Ongoing clinical trials coupled with expansion of biotech companies in the EMEA region
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Antibody Therapeutics Market, by Format

• 6.1. Introduction
• 6.2. Antibody Fragment
• 6.3. Bispecific Antibody
• 6.4. Monoclonal Antibody
• 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

• 8.1. Introduction
• 8.2. Chimeric
• 8.3. Human
• 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

• 9.1. Introduction
• 9.2. Autoimmune & Inflammatory Diseases
• 9.3. Hematology
• 9.4. Immunology
• 9.5. Neurology
• 9.6. Oncology
• 9.7. Osteology

10. Antibody Therapeutics Market, by End User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Long-term Care Facilities

11. Americas Antibody Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Antibody Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
  • 14.3.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
  • 14.3.3. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
  • 14.3.4. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
  • 14.3.5. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
  • 14.3.6. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
  • 14.3.7. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody
  • 14.3.8. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
  • 14.3.9. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
  • 14.3.10. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
  • 14.3.11. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
  • 14.3.12. Merck to Develop mAb Through USD 10.8 Billion Acquisition
  • 14.3.13. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio